BRÈVE

sur Baloise Holding AG (isin : CH0012410517)

Charles Ischi AG Wins InnoPrix SO! Award for Pharmaceutical Innovation

Charles Ischi AG, a Swiss company known for creating testing devices for tablets and capsules, has been awarded the 2024 InnoPrix SO! for its DISI Evo disintegration tester. This innovative device is designed to accurately measure the breakdown time of medications, a critical factor for ensuring drug efficacy. The tester is particularly beneficial for analyzing complex delayed-release tablets that contain multiple active ingredients.

The DISI Evo stands out for its ability to test a wide range of products, including hard and soft capsules, mini tablets, and even the smallest doses with micro-discs. Its user-friendly design suits modern laboratories aiming for efficiency. This technological advancement was developed in collaboration with regional partners, highlighting Solothurn's innovative capacity and Switzerland's status as a leading technology hub.

Recognized for its maturity and broad applicability, the innovation won Charles Ischi AG a prize of CHF 25,000. The annual InnoPrix SO!, presented by Baloise Bank Ltd's foundation since 1987, encourages projects that stimulate the Solothurn economy.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Baloise Holding AG